Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gastric bypass limb lengths: a key to better metabolic outcomes?

NCT ID NCT05471037

Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how changing the length of the small intestine re-routed during gastric bypass surgery affects metabolism and inflammation. Researchers will compare two surgical techniques in 50 people with severe obesity and also include 15 healthy lean individuals as a comparison group. The goal is to understand the underlying metabolic mechanisms, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gastric bypass surgery with different limb lengths
What this could lead to
If successful, this could help doctors choose the best surgical technique to improve metabolic health after gastric bypass.
What could go wrong
This is a small, early-stage study with only 65 participants, so results may not apply to everyone. It focuses on understanding mechanisms, not on proving a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 65 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2022

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 2 x 25 patients with morbid obestiy (BMI of 35 kg/m2 or higher) who comply with the regulatory rules for bariatric surgery in Switzerland (SMOB guidelines) and participate in the SLIM Trial * 15 healthy lean controls Exclusion Criteria: * general contraindications to kind of surgery * known or suspected non-compliance * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders etc. of the participant * participation in another interventional study * BMI \> 60 kg/m2 * height \< 145 cm * CL length of \< 180 cm as measured intraoperatively * ASA physical status classification \> III * inflammatory bowel disease * diabetes * intake of corticosteroids, anti-inflammatory/ immunosuppressive drugs potentially altering immune cells * clinical signs of current infection * known anemia (e.g. hemoglobin \< 110g/L for males, \< 100g/L for females) * known neutropenia (e.g. leucocyte count \< 1.5 x 10\^9/L or ANC \< 0.5 x 10\^9/L) * known immunodeficiency, e.g. HIV * known vasculitis, collagenosis * known adrenal insufficiency and/or substitution with glucocorticoids * risky daily alcohol consumption (\> 24g/d for males, \> 12g/d for females) * drug abuse * known liver cirrhosis Child B or C * known uncontrolled congestive heart failure * known uncontrolled malignant disease * currently pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity, morbid are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

morbid obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity, morbid

Contacts and locations

Locations

  • St Clara Research Ltd, St Claraspital Basel

    Basel, 4002, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.